| Trial registration number
|
EUCTR2021-000905-26-SE |
Full text link
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000905-26/SE
|
First author
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Department of Oncology, Uppsala University Hospita - Department of Oncology
|
Contact
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
gunilla.enblad@igp.uu.se
|
Registration date
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
2021-03-12
|
Recruitment status
Last imported at : Feb. 5, 2025, midnight
Source : EU Clinical Trials Register
|
Completed
|
Study design
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
nonRCT
|
Allocation
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Non-randomized
|
Design
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Parallel
|
Masking
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Open label
|
Center
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
single-center
|
Study aim
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Prevention
|
Inclusion criteria
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Age 18 years or older
Treatment for cancer within 6 month with CD20-depleting therapy and/or check-point inhibitors and/or chemotherapy
|
Exclusion criteria
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Unable to give informed consent
Subject is not eligible to receive Covid-19 vaccine according to current reccommendations from the Public Health Agency of Sweden.
Subject has a known hypersensitivity to the active substance or to any of the components of the investigational medical product, as specified in the product’s Summary of Product Characteristics, SmPC .
Estimated life expectancy of less than three months.
|
Number of arms
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
3
|
Funding
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Department of Oncology, Uppsala University Hospita
|
Inclusion age min
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
18
|
Inclusion age max
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
100
|
Countries
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Sweden
|
Type of patients
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
High risk patients
|
Severity scale
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
N/A
|
Total sample size
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
150
|
primary outcome
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
SARS-CoV2 specific immunoglobulin responses
SARS-CoV2-antigen induced T cell responses
|
Notes
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
nan
|
Phase
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
Phase 4
|
Arms
Last imported at : April 1, 2021, 8:13 p.m.
Source : EU Clinical Trials Register
|
[{"arm_notes": "Comirnaty", "treatment_id": 339, "treatment_name": "Covid-19 mrna vaccine (nucleoside-modified)", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "COVID-19 Vaccine Moderna", "treatment_id": 339, "treatment_name": "Covid-19 mrna vaccine (nucleoside-modified)", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "VaxZevria", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]
|